Profile data is unavailable for this security.
About the company
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
- Revenue in USD (TTM)4.57m
- Net income in USD-484.27m
- Incorporated2014
- Employees411.00
- LocationRevolution Medicines Inc700 Saginaw DrREDWOOD CITY 94063-4752United StatesUSA
- Phone+1 (415) 766-3638
- Fax+1 (302) 636-5454
- Websitehttps://www.revmed.com/
More ▼
Mergers & acquisitions
| Acquired company | RVMD:NSQ since announced | Transaction value |
|---|---|---|
| EQRX Inc | 50.51% | 1.58bn |
Data delayed at least 15 minutes, as of May 23 2024 15:04 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.48bn | 550.00 | -- | -- | -- | 25.06 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.55bn | 927.00 | -- | 18.69 | -- | 7.14 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.65bn | 10.00k | 5.39 | 117.05 | 4.37 | 0.8898 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.79bn | 373.00 | 18.81 | 32.53 | 14.44 | 6.71 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.12bn | 1.31k | 32.48 | 2.91 | 26.56 | 3.31 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 6.21bn | 423.00 | -- | -- | -- | 1,655.25 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.43bn | 645.00 | -- | 20.69 | -- | 22.79 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.56bn | 411.00 | -- | 3.80 | -- | 1,437.04 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.65bn | 2.80k | 21.77 | 1.80 | 6.79 | 1.73 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 6.95bn | 28.00 | -- | 7.44 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.11bn | 610.00 | -- | 10.94 | -- | 13.83 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.59bn | 355.00 | -- | 13.42 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.62bn | 420.00 | 40.60 | -- | 32.20 | 4.13 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 7.76bn | 254.00 | -- | 3.91 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
Data as of May 23 2024. Currency figures normalised to Revolution Medicines Inc's reporting currency: US Dollar USD
49.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Mar 2024 | 14.71m | 8.94% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 14.43m | 8.76% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 10.12m | 6.15% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 7.55m | 4.58% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 7.51m | 4.56% |
| BVF Partners LPas of 31 Mar 2024 | 5.98m | 3.63% |
| Casdin Capital LLCas of 31 Mar 2024 | 5.62m | 3.41% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.39m | 3.27% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 5.07m | 3.08% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.67m | 2.84% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
